期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌患者循环肿瘤DNA的研究进展 被引量：6

Progress in Circulating Tumor DNA in Non-small Cell Lung Cancer Patients
原文传递
导出
摘要 循环游离DNA以细胞外游离形式存在于血液中,可由正常细胞和癌细胞释放。非小细胞肺癌(NSCLC)患者血液中游离DNA水平高于正常人,且循环游离DNA可以反映癌组织的基因突变,甲基化状态,拷贝数改变,杂合子丢失等特征,是肺癌诊断、治疗、预后检测中具有巨大潜力的生物学指标。本综述简要介绍了循环游离DNA的生物学特性,并对近年来循环游离DNA基因改变检测在NSCLC中的临床应用进行阐述。 Circulating-cell-free DNA（cf DNA）,Which is released by normal cells or tumor cells,is defined as extracellular DNA in the blood.The cf DNA levels in non-small cell lung cancer（NSCLC）patients are higher than those in healthy controls. cf DNA also carries the features of tumor tissue,such as mutations,methylations,copy number changes,and loss of heterozygosis.cf DNA is apotential biomarker in the diagnosis,management,and prognosis of NSCLC. The biological features of cf DNA,and its clinical utility as a blood biomarker in genomic alterations in NSCLC is reviewed.
作者 高胜男 张嘉玲 呼群
机构地区 内蒙古医科大学附属医院
出处 《肿瘤学杂志》 CAS 2016年第3期172-175,共4页 Journal of Chinese Oncology
基金 国家自然科学基金地区科学基金项目(81160253)
关键词 循环游离DNA 循环肿瘤DNA 肿瘤标志物 非小细胞肺癌 circulating-cell-free DNA circulation tumor DNA cancer biomarker non-small cell lung cancer
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献33

  • 1Vilmann P,Clementsen PF,Colella S,et al. Combined en- dobronchial and esophageal endosonography for the diag- nosis and staging of lung cancer:European Society of Gastrointestinal Endoscopy (ESGE) guideline,in coopera- tion with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) [J].[J].[n- doscopy, 2015,47(6) : 545-559.
  • 2Ying M,Zhu XX,Zhao Y,et al. KRAS mutation as a biomarker for survival in patients with non-small cell lung cancer,a meta-analysis of 12 randomized trials [J]. Asian Pac I Cancer Prey,2015,16(10):4439-4445.
  • 3Kukec RR,Grabnar I,Vovk T,et al,Febrile neutropenia in chemotherapy treated small-cell lung cancer patients[J]. Radiol Oncol, 2015,49(2) : 173-180.
  • 4Luo YH,Chen YM. Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance [J]. Transl Lung Cancer Res, 2014,3(6) : 368-369.
  • 5Yang YL,Jablons D,You L. An alternative way to initiate Notchl signaling in non-small cell lung cancer [J]. Transl Lung Cancer Res, 2014,3(4) : 238-241.
  • 6Nakao M,Muramatsu H,Sone K,et al. Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older:a retrospec- tive analysis[J]. Mol Clin Oncol,2015,3(2):403-407.
  • 7Oikawa T,Ohira T,Otani K,et al. Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epi- dermal growth factor receptor mutation [J]. Mol Clin On-.col, 2015,3(2) :329-333.
  • 8Cascales A,Martinetti F,Belemsagha D,et al. Challenges in the treatment of early non-small cell lung cancer:what is the standard,what are the challenges and what is the future for radiotherapy? [J]. Transl Lung Cancer Res, 2014,3(4) : 195-204.
  • 9Nel I,Jehn U, Gauler T,et ah Individual profiling of circu- lating tumor cell composition in patients with non-small cell lung cancer receiving platinum based treatment [J]. Transl Lung Cancer Res,2014,3(2): 100-106.
  • 10Masago K,Fujimoto D,Fujita S,et al. Response to beva- cizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer[J]. Mol Clin Oncol,2015,3(2):415-419.

二级参考文献9

  • 1SambrookJ FritschEF ManiatisT(美) 金冬雁 黎孟枫 译 侯云德 校.分子克隆实验指南[M].北京:科学出版社,1999.30-32.
  • 2Dy GK, Adjei AA. Novel target for lung cancer therapy: part I. Clin Oncol, 2002, 20:2 881 -2 884.
  • 3Sozzi G, Pastorino U, Moiraghi L et al. loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res,1998,58:5 032 - 5 037.
  • 4Sozzi G, Musso K, Ratcliffe C et al . Detection of microsatellite alterations in plasma DNA of non - small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res,1999,5:2 689 - 2 692.
  • 5Jahr S, Hentze H, Englisch S et al . DNA fragments in the blood plasma of cancer patients: Quantitation and evidence for their origin from apoptotic and necrotic cell. Cancer Res,2001, 61:1 659- 1 665.
  • 6Sozzi G, Conte D, Mariani L et al . Analysis of circulating tunmur DNA in plasma at diagnosis and during follow- up of lung cancer patients. Cancer Res,2001, 61:4 675 - 4 678.
  • 7Powell CA, Klares S, O' Connor G et al . Loss of heterozygosity in epithelial cell obtained by bronchial brushing: clinical utility in lung cancer. Clin Cancer Res, 1999, 5 : 2025 - 2034.
  • 8高玉彤,来茂德.检测微卫星不稳定性的银染色方法[J].临床与实验病理学杂志,1998,14(2):193-194. 被引量：13
  • 9易斌,杨和平,阮志华.小细胞肺癌血浆中游离性DNA的3p位点杂合性缺失[J].第三军医大学学报,2003,25(4):341-343. 被引量：1

共引文献2

同被引文献36

引证文献6

二级引证文献41

肿瘤学杂志
2016年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部